BACKGROUND: Inner-city children experience disproportionate asthma morbidity, and suspected reasons include indoor environmental exposures. OBJECTIVE: To determine if mouse allergen exposure is a risk factor for asthma morbidity. METHODS: Preschool children with asthma were recruited from inner-city Baltimore, MD. Skin testing was performed and blood was collected at the baseline visit for quantification of mouse allergen specific IgE. A questionnaire evaluated symptoms, medication, and health care use at baseline, 3 months, and 6 months. A trained technician collected dust samples from the child's home for analysis of Mus m 1 at baseline, 3 months, and 6 months. Outcomes were compared between mouse-sensitized, highly exposed children and all other children. RESULTS: A total of 127 children had complete data for mouse sensitization status and bedroom settled dust mouse allergen levels at baseline. The mean age of the children was 4.4 years, 92% were African American, and 26% were sensitized to mouse. Mouse-sensitized children exposed to higher levels of Mus m 1 (>0.5 microg/g) had 50% more days of symptoms (incidence rate ratio [IRR], 1.5; 95% confidence interval [CI], 1.1-2.1) and 80% more days of beta-agonist use than other children (IRR, 1.8; 95% CI, 1.3-2.5). Children in the sensitized and highly exposed group were also more likely to have an unscheduled physician visit (odds ratio [OR], 3.1; 95% CI, 1.6-6.3), emergency department visit (OR, 2.1; 95% CI, 1.1-4.1), and hospitalization (OR, 36.6; 95% CI, 4.1-327.3) than other children. These associations between mouse allergen exposure and asthma symptoms and morbidity remained statistically significant after adjusting for potential confounders, including atopy and cockroach sensitization and exposure. CONCLUSIONS: In mouse-sensitized inner-city children, exposure to mouse allergen may be an important cause of asthma morbidity.
BACKGROUND: Inner-city children experience disproportionate asthma morbidity, and suspected reasons include indoor environmental exposures. OBJECTIVE: To determine if mouse allergen exposure is a risk factor for asthma morbidity. METHODS: Preschool children with asthma were recruited from inner-city Baltimore, MD. Skin testing was performed and blood was collected at the baseline visit for quantification of mouse allergen specific IgE. A questionnaire evaluated symptoms, medication, and health care use at baseline, 3 months, and 6 months. A trained technician collected dust samples from the child's home for analysis of Mus m 1 at baseline, 3 months, and 6 months. Outcomes were compared between mouse-sensitized, highly exposed children and all other children. RESULTS: A total of 127 children had complete data for mouse sensitization status and bedroom settled dust mouse allergen levels at baseline. The mean age of the children was 4.4 years, 92% were African American, and 26% were sensitized to mouse. Mouse-sensitized children exposed to higher levels of Mus m 1 (>0.5 microg/g) had 50% more days of symptoms (incidence rate ratio [IRR], 1.5; 95% confidence interval [CI], 1.1-2.1) and 80% more days of beta-agonist use than other children (IRR, 1.8; 95% CI, 1.3-2.5). Children in the sensitized and highly exposed group were also more likely to have an unscheduled physician visit (odds ratio [OR], 3.1; 95% CI, 1.6-6.3), emergency department visit (OR, 2.1; 95% CI, 1.1-4.1), and hospitalization (OR, 36.6; 95% CI, 4.1-327.3) than other children. These associations between mouse allergen exposure and asthma symptoms and morbidity remained statistically significant after adjusting for potential confounders, including atopy and cockroach sensitization and exposure. CONCLUSIONS: In mouse-sensitized inner-city children, exposure to mouse allergen may be an important cause of asthma morbidity.
Authors: Lindsay Rosenfeld; Ginger L Chew; Rima Rudd; Karen Emmons; Luis Acosta; Matt Perzanowski; Dolores Acevedo-García Journal: J Urban Health Date: 2011-02 Impact factor: 3.671
Authors: Elizabeth C Matsui; Matthew Perzanowski; Roger D Peng; Robert A Wise; Susan Balcer-Whaley; Michelle Newman; Amparito Cunningham; Adnan Divjan; Mary E Bollinger; Shuyan Zhai; Ginger Chew; Rachel L Miller; Wanda Phipatanakul Journal: JAMA Date: 2017-03-14 Impact factor: 56.272
Authors: Patrick N Breysse; Gregory B Diette; Elizabeth C Matsui; Arlene M Butz; Nadia N Hansel; Meredith C McCormack Journal: Proc Am Thorac Soc Date: 2010-05
Authors: Wanda Phipatanakul; Augusto A Litonjua; Thomas A E Platts-Mills; Lisa M Naccara; Juan C Celedón; Hassen Abdulkerim; Elaine B Hoffman; Diane R Gold Journal: J Allergy Clin Immunol Date: 2007-06-25 Impact factor: 10.793
Authors: Wanda Phipatanakul; Petros Koutrakis; Brent A Coull; Choong-Min Kang; Jack M Wolfson; Stephen T Ferguson; Carter R Petty; Mihail Samnaliev; Amparito Cunningham; William J Sheehan; Jonathan M Gaffin; Sachin N Baxi; Peggy S Lai; Perdita Permaul; Liming Liang; Peter S Thorne; Gary Adamkiewicz; Kasey J Brennan; Andrea A Baccarelli; Diane R Gold Journal: Contemp Clin Trials Date: 2017-06-12 Impact factor: 2.226
Authors: William J Sheehan; Pitud A Rangsithienchai; Michael L Muilenberg; Christine A Rogers; Jeffrey P Lane; Jalal Ghaemghami; Donald V Rivard; Kanao Otsu; Elaine B Hoffman; Elliot Israel; Diane R Gold; Wanda Phipatanakul Journal: Ann Allergy Asthma Immunol Date: 2009-02 Impact factor: 6.347